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ANALYSE DE L'EXPRESSION D’ERBIN ET D’ERB-B2 DANS 
LES TUMEURS CUTANEES NON MELANOCYTAIRES. 
 
 
Résumé 
Introduction. ERBIN est une nouvelle protéine de la famille des LAP (pour Leucine rich And 
PDZ domain)), identifiée comme partenaire de liaison d’Erb-B2. Ce dernier est un membre de 
la famille des récepteurs à l’EGF, jouant un rôle crucial dans la régulation de la croissance 
cellulaire et de la différentiation. Bien que sa fonction reste non élucidée, des études récentes 
ont montré qu’ERBIN affecte la polarité des cellules de l’épithélium et la croissance cellulaire 
par la voie de signalisation Ras. 
Objectif. Examiner et comparer la distribution tissulaire et le niveau d’expression d’ERBIN et 
d’Erb-B2 dans la peau normale et dans certaines tumeurs cutanées non mélanocytaires. 
Méthode. Quinze cas de carcinomes basocellulaires (BCC), 12 cas de carcinomes 
spinocellulaires (SCC) et 5 cas de kératoacanthome (KA) ont été analysés par 
immunohistochimie sur des sections de tissus paraffinés en utilisant des anticorps contre 
ERBIN et Erb-B2. 
Résultats. ERBIN et Erb-B2 ont une distribution similaire dans la peau. Ils sont localisés au 
niveau de la membrane plasmique, aussi bien dans les kératinocytes différentiés que dans les 
cellules des canaux des glandes eccrines. Par contre, leur localisation est diffuse et 
cytoplasmique dans les kératinocytes interfolliculaires basaux. Pour ERBIN, le niveau 
d’expression est inchangé dans les BCC et SCC, contrairement à Erb-B2. L’expression de ce 
dernier est augmentée dans les BCC alors quelle est diminuée dans les SCC. Dans les BCC, la 
distribution subcellulaire d’ERBIN et d’Erb-B2 est altérée, tandis que pour les SCC et les KA 
leur distribution subcellulaire n’est pas affectée. 
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Conclusions. La localisation subcellulaire d’ERBIN dans la peau normale humaine est 
similaire à celle d’Erb-B2 et varie en fonction de la différentiation cellulaire. Sur la base des 
activités biologiques connues d’ERBIN et de nos résultats, il est probable que la perturbation 
de l’expression et/ou de la fonction de ERBIN et d’Erb-B2 soit impliquée dans le 
développement du phénotype malin des BCC et des SCC. Ces deux protéines pourraient 
coopérer dans les voies de signalisation impliquées dans le développement du phénotype 
malin. 
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Introduction 
Les carcinomes sont les plus fréquentes tumeurs de la peau dans la population blanche et ont 
un impact substantiel sur les coûts de la santé (1). Deux types de tumeur non mélanocytaires 
se distinguent: le carcinome basocellulaire (BCC) et le carcinome spinocellulaire (SCC). Ils se 
développent de façon préférentielle dans les zones cutanées exposées aux rayons UV du 
soleil. Ces deux tumeurs peuvent provoquer un envahissement locorégional ainsi qu’une 
destruction tissulaire significative. De plus, les SCC font des métastases occasionnellement. 
Par analogie avec d’autres tumeurs, leur développement a été associé à la succession de 
mutations au niveau moléculaire, incluant des gènes suppresseurs de tumeur, comme p53 ou 
des oncogènes, comme Ras, Myc et les membres de la famille des récepteurs tyrosine kinase 
(RTK) (2).  
La famille Erb-B des récepteurs à tyrosine kinases (RTK) comprend le récepteur Epidermal 
Growth Factor (EGFR, aussi appelé Erb-B1 ou HER1), Erb-B2 (aussi appelé HER2 ou Neu), 
Erb-B3 (ou HER3) et Erb-B4 (ou HER4). Structurellement, ces récepteurs ont une 
organisation similaire comportant un domaine extracellulaire glycosylé liant les ligands, un 
domaine transmembranaire hydrophobe et un domaine catalytique cytoplasmique hautement 
conservé d’un récepteur à l’autre. Après liaison de leurs ligands, ces récepteurs forment des 
complexes homo- et hétéro-dimériques, déclenchant une cascade de signalisation 
intracellulaire. Jusqu’à aujourd’hui, aucun ligand n’a été identifié pour Erb-B2 (3). 
L’expression conjointe de certains hétérodimères pourrait être décisive pour l’induction ou le 
maintien du phénotype malin (3). En effet, l’expression d’HER2 et l’expression concomitante 
d’EGFR/HER2 sont retrouvées préférentiellement dans la peau normale, tandis que 
HER2/HER3 et la triple expression d’EGFR/HER2/HER3 sont détectés plus fréquemment 
dans les BCC et les SCC en comparaison à la peau normal (4). De plus, la famille des 
récepteurs Erb-B joue un rôle fondamental dans la prolifération cellulaire (5-7) et la motilité 
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cellulaire (8,9). Enfin, l’expression anormale de récepteurs Erb-B, comme Erb-B1 et Erb-B2, 
a été impliquée dans le développement de nombreux types de cancers humains, comme les 
cancers du sein et des ovaires (3). Les données actuelles suggèrent que ces récepteurs 
contribuent ou sont responsables de la tumorogenèse, soit par leur sur-expression due à 
l’amplification génique, soit par l’accroissement de leur transcription.  
 
Dans la peau normale, en utilisant un marquage immunohistochimique, EGFR est retrouvé au 
niveau de la membrane cellulaire de toutes les couches de l’épiderme (10). Néanmoins, son 
niveau d’expression diminue progressivement dans les couches plus différenciées et dans la 
couche cornée. Par contre, Erb-B2 est retrouvé dans une distribution cytoplasmique au niveau 
des cellules de la couche basale, tandis qu’il se situe au niveau des membranes cellulaires 
dans les couches suprabasales de l’épiderme (11 dans cette étude). Erb-B2 a la même 
distribution dans la gaine externe du follicule pileux et dans la portion sécrétrice de la glande 
eccrine (12). Dans les carcinomes cutanés, l’expression d’Erb-B2 est variable selon les études 
et reste donc à clarifier. En effet, Ahmed et collaborateurs ont trouvé, par immunohistochimie, 
que l’expression d’Erb-B2 était réduite ou inchangée dans les BCC mais significativement 
augmentée dans les SCC (13). Par contre, une autre étude n'a pas détecté d'expression d’Erb-
B2 dans 49 cas de SCC (14).  
Le rôle important d’Erb-B2 dans l'homéostasie cutanée a été confirmé par de multiples 
models murins. Dans les souris transgéniques, l’expression constitutive de la forme activée ou 
sauvage d’Erb-B2 dans les cellules de l’épiderme basal grâce à l’utilisation des promoteurs 
K5 (15) ou K14 (16) mène a une hyperplasie épidermique de la peau et d’autres organes, 
conduisant à la mort. Récemment, plusieurs laboratoires ont identifié une protéine nommée 
ERBIN (pour Erb-B2-Interacting Protein) qui appartient à la famille des protéines LAP (pour 
Leucin rich And PDZ domaine) (17, 18). Différentes isoformes de cette protéine existent et 
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sont exprimées dans la plupart des tissus humains. Néanmoins, ERBIN semble exprimée de 
façon abondante dans le cerveau, le cœur, le rein, le muscle et l’estomac (18). ERBIN a été 
retrouvée localisée sur la membrane basolatérale ou diffusément dans le cytoplasme en 
fonction des cellules examinées (17, 18). ERBIN interagit notamment avec Erb-B2 et régule 
sa distribution subcellulaire (17). De plus, ERBIN interagit aussi avec PSD-95 (19), lano (20) 
et avec trois p120-related catenins (21,22) : d-Catenin, ARVCF et p0071 (aussi appelé 
plakophilin-4), une « armadillo repeat protein » lié au cytosquelette.  
ERBIN interagit également avec eBPAG1 et la sous-unité b4 de l’intégrine a6b4, deux 
composants majeurs des hémidesmosomes (18). Bien que sa fonction exacte reste à identifier, 
ERBIN pourrait être impliquée dans régulation de la polarité des cellules épithéliales. 
Finalement, des études récentes révèlent qu’ERBIN peut fonctionner comme un suppresseur 
de la voie de signalisation de Ras (23) 
 En raison du rôle critique potentiel de ERBIN et d’Erb-B2 dans le maintien de 
l’homéostasie cutanée, nous avons ici analysé par des approches biochimiques et 
immunohistochimiques l’expression de celles-ci dans la peau saine humaine et dans les 
carcinomes basocellulaires, spinocellulaires et les keratoacanthomes cutanés.  
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Summary 
 
Background ERBIN, is a binding partner of Erb-B2, an orphan receptor within the Erb-B family 
critically involved in the regulation of cell growth and differentiation. Although its function 
remains unclear, ERBIN is thought to affect the polarity of epithelial cells and cell growth via the 
Ras signalling pathway. 
Objectives To examine and compare the tissue distribution and the expression levels of ERBIN 
and Erb-B2 in normal skin and in cutaneous carcinomas. 
Methods Fifteen cases of basal cell carcinoma (BCC), 12 cases of squamous cell carcinoma (SCC), 
and 5 cases of keratoacanthoma (KA) were analysed by immunohistochemistry on paraffin-
embedded sections using anti-ERBIN and anti-Erb-B2 antibodies. 
Results ERBIN and Erb-B2 had a similar distribution in normal human skin. They were primarily 
localized at the plasma membrane in differentiated keratinocytes and in duct cells from eccrine 
glands, whereas they were localized diffusely in the cytoplasma of basal keratinocytes. In both 
SCC and KA the subcellular distribution of ERBIN and Erb-B2 remained unchanged whereas both 
proteins were redistributed from the plasma membrane into cytosolic aggregates in BCC. 
Conclusion The subcellular localization of ERBIN in normal human skin is similar to that of Erb-
B2 and varies with cell differentiation. Based on our findings and on the biological activities of 
Erb-B2, it is conceivable that disturbed expression or functioning of ERBIN and Erb-B2 is 
implicated in the development of the malignant phenotype of BCC. 
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Introduction 
 
Cutaneous carcinomas are the most frequent tumours occurring in the white population and 
have a substantial impact on public health 1. Two major tumour types are distinguished, basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) that predominantly arises in sun-exposed 
sites. They can both invade locally, resulting in significant tissue destruction. Furthermore, SCCs 
occasionally metastasize. In analogy to other neoplasms, their development has been linked to 
various signalling pathways involving either tumour suppressor genes such as p53 or oncogenes 
such as Ras, Myc and the Erb-B family of receptor tyrosine kinases (RTK) 2. 
 The Erb-B family of RTKs includes the epidermal growth factor receptor (EGFR, 
also called Erb-B1 or HER1), Erb-B2 (also HER2 or Neu), Erb-B3 (or HER3) and Erb-B4 (or 
HER4). The expression pattern of Erb-B receptors is thought to be critical for the induction and 
maintenance of the malignant phenotype. Indeed, expression of both HER2 and HER3 or the 
concomitant expression of EGFR, HER2 and HER3 has been observed more frequently in BCC 
and SCC when compared with normal skin 3. Furthermore, Erb-B receptors play fundamental roles 
in cell proliferation 4-6 and cell motility 7,8. Finally, abnormal expression of Erb-B receptors, such 
as that of Erb-B1 and Erb-B2, has been implicated in the development of numerous types of 
human neoplasms, such as breast and ovarian cancers 9. 
 In normal human epidermis, EGFR displays a plasma membrane staining 
throughout all cell layers. Its expression level gradually decreases towards the stratum corneum. In 
contrast, Erb-B2 displays a cytoplasmic staining in the basal cell layer, while it exhibits a plasma 
membrane staining in the upper suprabasal layers (this study) 10,11. Erb-B2 is also found in the 
external root sheath of hair follicules and in eccrine gland secretory cells 12. Its expression remains 
unclear in cutaneous carcinomas13,14. However, in transgenic mice, the constitutive expression of 
the activated or wild-type form of Erb-B2 to epidermal basal cells using either the keratin 5 15 or 
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the keratin 14 16 promoter leads to progressive epithelial hyperplasia in skin and other organs, that 
ultimately results in death.  
Several laboratories, including ours, have recently identified a protein named ERBIN that 
belongs to the LAP (for Leucine rich and PDZ domain containing proteins) protein family 17,18. 
ERBIN specifically interacts with Erb-B2 and regulates its subcellular distribution 17. It localizes 
to the basolateral plasma membrane in intestinal epithelial and in transfected keratinocyte cell lines 
18. In addition, ERBIN also interacts with PSD-95 19, Lano 20 and with three p120-related catenins 
21,22, eBPAG1 and the b4 subunit of the a6b4 integrin, two major components of hemidesmosomes 
18. Although its exact function remains unclear, ERBIN is thought to be important for the polarity 
of epithelial cells. Finally, recent studies reveal that ERBIN can function as a suppressor of the Ras 
signaling pathway 23. 
As ERBIN and ERB-B2 may cooperatively contribute to the maintenance of skin 
homeostasis, we investigated the expression of ERBIN and Erb-B2 in normal human skin as well 
as in cutaneous carcinomas to gain better understanding of their function. 
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Materials and methods 
Cell culture and protein extracts 
Immortalized human keratinocytes were seeded on glass coverslips and maintained in 
Keratinocyte-SFM medium (Invitrogen, Basel, Switzerland). Keratinocyte differentiation was 
induced by incubation in Ham’s F12 : Dulbecco’s modified Eagle’s medium (DMEM) (1:3) 
(Invitrogen) as described 18. HaCaT cells were grown in DMEM (Invitrogen) supplemented with 
10% (vol/vol) fetal calf serum, 100 U mL-1 penicillin, and 100 U ml-1 streptomycin. The cells were 
maintained at 37° C in a humidified, 5% CO2 atmosphere.  
Total cell extracts were prepared by scraping cells grown on plastic using sodium dodecyl sulphate  
(SDS)-sample buffer. To analyze the subcellular distribution of ERBIN, cultured cells were 
scraped in ice-cold buffer A (50 mmol L-1 HEPES pH 7.5, 10% (vol/vol) glycerol, 150 mmol L-1 
NaCl, 1.5 mmol L-1 MgCl2 1 mmol L-1 EGTA, 10μg mL-1 of each of leupeptin, pepstatin, 
aprotinin) and disrupted by sonification at 50 W for 15 sec. Homogenates were spun down at 100 
000 g for 1 h at 4 °C. The supernatant corresponding to the cytosolic fractions was then collected 
whereas the pellet was resuspended in buffer A supplemented with 1% (vol/vol) triton X-100, 
incubated for 15 min on ice and centrifuged at 100 000 g for 1h at 4 °C. Thereafter, the supernatant 
corresponding to the membrane fraction was collected, while the pellet constituting the 
cytoskeletal fraction was solubilized in SDS-sample buffer. Proteins were quantified using the DC 
protein assay (Biorad, Hercules, CA, U.S.A.) with bovine serum albumin (BSA) as standard. 
Antibodies 
Polyclonal anti-ERBIN antibodies were produced by injecting soluble glutathione-S-transferase-
ERBIN fusion proteins (encompassing residues 805-1179 or 1307-1412 of human ERBIN) in 
rabbits according to standard procedures. The anti-ERBIN antiserum directed against residues 805-
1179 of ERBIN was subsequently affinity purified with a His-tagged recombinant protein of 
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ERBIN. Purified immunoglobulins (polyclonal antibody (pAb) 139) were used at 3 µg ml-1 for 
immunohistochemistry and 0.1 µg mL-1 for Western blotting. The anti-ERBIN antiserum raised 
against residues 1307-1412 of ERBIN was sequentially purified on a protein-A column. The 
resulting total IgG (pAb 1646) was used at 1 µg mL-1 for Western blotting. pAb 1646 reacted 
weakly with ERBIN in immunohistochemistry and immunofluorescence studies but strongly in 
Western blot. Negative control performed with purified IgG from preimmune serum gave no 
background. Mouse monoclonal antibody (mAb) antihuman Erb-B2 (clone 3B5; Pharmingen, San 
Diego, CA, U.S.A.), recognizing residues 1242-1255 in the C-terminal domain of Erb-B2, was 
used at 2.5 µg mL-1. Mouse mAb anti-integrin b4 subunit (clone 450-11 A) was a generous gift 
from R. Falcioni (Molecular Oncogenesis Laboratory, Rome, Italy), mouse mAb anticytokeratin 
14 was purchased from Chemicon (Temecula, CA, U.S.A), horseradish peroxidase (HRP)-
conjugated goat antirabbit IgG and goat antimouse IgG were from BioRad, Alexa-488-conjugated 
goat antirabbit IgG was from Molecular Probes (Eugene, OR, U.S.A.), and biotinylated F(ab’)2 
fragments of rabbit antimouse immunoglobulins and biotinylated swine antirabbit 
immunoglobulins were from Dako (Glostrup, Denmark). 
 
Western blot analysis 
Forty micrograms  (total extracts) and 25 µg (cell fractionation) of proteins were resolved by SDS-
polyacrylamide gel electrophoresis under reducing conditions using 6% or 10 % gels and 
electrotransferred on to nitrocellulose membranes. Immune-reactive proteins were detected using 
enhanced chemilumescence reagent (Amersham Pharmacia Biotech, St Albans, U.K.). 
Immunofluorescence studies 
Cultured cells were fixed for 10 min in phosphate-buffered saline (PBS) containing 1% (w/v) 
paraformaldehyde and permeabilized with 0.1% (v/v) triton X-100 in PBS. After blocking 
nonspecific binding sites in 2% (w/v) BSA in PBS, cells were incubated with the primary antibody 
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pAb 139 (at 1 µg ml-1) diluted in PBS supplemented with 0.2% BSA (w/v). After washing, cells 
were incubated with Alexa-488 conjugated goat antirabbit IgG (Molecular Probes), then washed 
extensively, mounted in Prolong antifade reagent (Molecular Probes) and viewed under a Zeiss 
Axiovert 200 microscope equipped with an Axiocam digital camera. 
Tissue Specimens 
Sections of formalin-fixed, paraffin-embedded tissue were obtained from two healthy 
subjects, 15 cases of BCC (adenoid solid type), five cases of keratoacanthoma (KA) and 12 cases 
of SCC, including seven cases that were well differentiated. These tissue specimens were collected 
from the register of the Pathology Unit of the Department of Dermatology (University Hospital of 
Geneva) during the year 2002-03. The main criterion for the choice of the specimen of BCC and 
SCC was the presence of normal human skin adjacent to the cutaneous carcinomas. The diagnosis 
of KA on fully excised lesions was made based on well-recognized histological criteria described 
in major textbooks of dermatopathology 24. 
Immunoperoxydase staining. 
After being deparaffinized in xylene and absolute ethanol, the sections were placed in a jar filled 
with 1 mmol L-1 ethylenediamine tetraacetic acid, pH 7, and heated for 20 min. Endogenous 
peroxydase activity was inhibited by treatment with 0.5% of hydrogen peroxide in 50% methanol. 
Sections were blocked with 5% (w/v) BSA at room temperature, then incubated for 2 h with 
primary antibodies diluted in PBS supplemented with 0.5% (w/v) BSA. After washing, sections 
were incubated for 1 hour with biotinylated secondary antibody diluted in PBS supplemented with 
4% (w/v) BSA. Immune-reactivity was detected using the streptABComplex/HRP system from 
Dako with 3,3’-diaminobenzidine tetrahydrochloride as substrate. Subsequently, slides were 
counterstained with haematoxylin and mounted in Eukitt mounting medium (Kindler, Freiburg, 
Germany). Immunohistochemical staining was evaluated by two independent observers using an 
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Olympus microscope. Results from the two observers were compared and disagreements settled by 
joint review and consensus. 
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Results 
Characterization of the anti-ERBIN antisera 
We have generated two different antisera directed against human ERBIN. The pAb 139 
recognizes residues 805-1179 located upstream from the PDZ domain encompassing a stretch 
shared by all known human isoforms of ERBIN 18, whereas the pAb 1646 binds to the PDZ 
domain of ERBIN. The specificity of these antibodies was first tested by immunoblotting on whole 
cell extracts prepared from a HaCaT cell line and an immortalized keratinocyte cell line. Both 
antibodies reacted with a protein of an apparent molecular weight 180 kDa, corresponding to 
ERBIN (Fig. 1A). In differentiated immortalized keratinocytes ERBIN expression appeared to be 
upregulated based on the intensity of the immunoreactivity of the ERBIN protein band observed 
by Western blotting.  
  We next tested the reactivity of the antibodies by immunofluorescence microscopy. While 
the pAb 1646 showed weak staining (data not shown), the pAb 139 diffusely stained the cytoplasm 
of nondifferentiated keratinocytes. In contrast, when differentiated immortalized keratinocytes 
were tested, a clear plasma membrane staining at the cell-cell contact was observed (Fig. 2). As 
these findings suggest that the subcellular distribution of ERBIN varies according to the state of 
differentiation of keratinocytes, we carried out biochemical studies. Therefore, cytosolic, 
membrane and cytoskeletal fractions were prepared from cultured cells. We first evaluated the 
efficiency of our fractionation procedure by immunoblotting using the b4 integrin subunit as a 
marker of the membrane fraction and the keratin 14 as a marker of the cytoskeletal fraction. As 
expected, the b4 integrin subunit was found predominantly in the membrane fraction, whereas a 
minor proportion was also identified in the cytoskeletal fraction (Fig. 1B) as described 25,26 . By 
contrast, keratin 14 was found enriched in the cytoskeletal fraction and, in a marginal amount, also 
in the soluble pool (Fig. 1B). As shown in Figure 1B, ERBIN is enriched in the membrane 
fractions obtained from both undifferentiated and differentiated keratinocytes. However, a 
 - 11 - 
significant amount of ERBIN was also found in the cytosolic and the cytoskeletal fractions. As 
expected, upon differentiation of the keratinocytes, there was a substantial increase of the amount 
of ERBIN in the membrane and the cytoskeletal fractions. 
 
Distribution of ERBIN and Erb-B2 in normal human skin  
As the pAb 1646 showed only weak reactivity, we subsequently used only the pAb 139 
antibody for all immunohistochemical analyses. On paraffin-embedded human skin sections, 
ERBIN expression was found in the epidermis, hair follicles and eccrine sweat glands (Fig. 3). In 
addition, there was a cytoplasmic staining of vascular blood endothelial cells and of some 
inflammatory mononuclear cells in the dermis (not shown). In the epidermis, the pAb 139 antibody 
produced a diffuse cytoplasmic staining of the keratinocytes of the basal cell layer, whereas in the 
upper epidermis a prominent plasma membrane staining pattern was found (Fig. 3 A). A similar 
membrane staining was also identified in the outer and inner sheath of hair follicles, as well as in 
the hair matrix (Fig. 3 C). In eccrine sweat glands, ERBIN was distributed diffusely in the 
cytoplasm of the cells located in the secretory portion of the gland (Fig. 3 E), whereas a more 
intense intercellular staining was observed in duct cells. In addition, there was a strong diffuse 
cytoplasmic staining of myoepithelial cells (Fig. 3 E, arrowhead). 
The anti-Erb-B2 antibody gave a staining pattern similar to that obtained with the anti-
ERBIN antibody (Fig. 3). However, Erb-B2 staining was predominantly found at the level of the 
plasma membrane, whereas the cytoplasmic diffuse staining appeared to be reduced (Fig. 3 B). 
Furthermore, a clear intercellular staining was identified in the upper epidermis, the outer and 
inner sheath of hair follicles and the hair matrix (Fig. 3 D). In eccrine glands, Erb-B2 was diffusely 
distributed in the cytoplasm of cells located in the secretory portions (Fig. 3 E), whereas duct cells 
showed an intercellular staining. In contrast to what was found with ERBIN, there was no staining 
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for Erb-B2 in myoepithelial cells encircling sweat glands (Fig. 3 F), in endothelial cells of vascular 
blood vessels or in inflammatory mononuclear cells (not shown).  
 
Expression of ERBIN and Erb-B2 in cutaneous carcinomas. 
The expression of ERBIN and Erb-B2 was further investigated in cutaneous carcinomas. The 
relative expression levels of ERBIN and Erb-B2 in BCC, SCC and KA were assessed based on 
their staining intensity in the tumour when compared with that of the adjacent normal skin. In 
addition, the subcellular distribution of Erb-B2 and ERBIN was analyzed.  
 In the 15 cases of BCC tested, almost all tumour cells were stained by the pAb 139 anti-
ERBIN antibody (Tables I and II). When compared with normal human skin, the intensity of 
staining of ERBIN appeared unchanged in 8 (53%) out of the 15 cases of BCC, while it was 
increased in the remaining seven (47%) cases. In contrast to what observed in the upper layer of 
normal human skin, the vast majority of BCCs, i.e. 13 (86%) of the 15 cases, did not show any 
plasma membrane staining for ERBIN. This distribution pattern of ERBIN in BCC cells was 
similar to that observed in basal keratinocytes of normal epidermis with a predominantly 
cytoplasmic staining. However, in a large proportion of BCCs, ERBIN was found in cytoplasmic 
aggregates (Fig. 4 A, C). These aggregates were found in 12 (80 %) of 15 cases of BCC (Table I), 
independently of whether or not ERBIN was overexpressed. Furthermore, tumour cells located 
where the basal cell carcinoma was connected to the epidermis also contained cytosolic aggregates 
of ERBIN (Fig. 4 A, insert). 
In the seven cases of BCC which overexpressed ERBIN there was also a concomitant 
overexpression of Erb-B2, which was detected in the same cytoplasmic aggregates (Fig. 4 B, D 
and Table I). 
In SCC, almost all tumor cells were stained utilizing the pAb 139 anti-ERBIN antibody, although 
the staining intensity was heterogeneous within the same tumor (Fig. 4 C). Specifically, while 
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some tumour cells showed moderately increased expression of ERBIN compared to the adjacent 
keratinocytes from the apparently normal epidermis, some individual cells showed stronger 
expression (Fig. 4 E, arrowhead). When the overall staining intensity of the tumor was considered 
for semiquantitative analysis, four (33 %) of the 12 SCC cases showed a reduced expression of 
ERBIN, while in the remaining eight cases (77%) the expression was comparable with that found 
in the adjacent apparently normal keratinocytes. The subcellular distribution of ERBIN in SCC 
was variable. In some tumors (42%) the polarized distribution of ERBIN at plasma membrane was 
maintained, whereas in others ERBIN showed a diffuse cytosolic distribution. In all cases of SCC 
in which ERBIN was found localized at the plasma membrane this polarized distribution was 
uniquely observed in the tumour cells which were at distance from the stromal tissue (not shown). 
This distribution pattern was reminiscent of that found in normal epidermis. 
In contrast to ERBIN, in SCC the expression level of Erb-B2 appeared to be strongly 
altered. The staining for Erb-B2 was significantly reduced in nine (75 %) of 12 SCC, whereas in 
two (16 %) cases it was completely absent (table II). Although the analysis was difficult, the 
distribution of Erb-B2 in tumor cells (Fig. 4 F) appeared to be similar to that in the adjacent normal 
epidermis. As in the case for ERBIN, Erb-B2 was found at the plasma membrane only in the 
keratinizing area of the tumour (Fig. 4 F). However, we found no correlation between the degree of 
tumor differentiation and the expression level of Erb-B2.  
Finally, there was no obvious difference in the subcellular distribution of ERBIN and Erb-
B2 in the five cases of KA analyzed when compared with that found in keratinocytes of normal 
skin sections (Fig. 4 G, H). Peripheral cells displayed a diffuse cytoplasmic staining for ERBIN, 
whereas in the innermost layers both ERBIN and Erb-B2 gave a prominent plasma membrane 
staining. 
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Discussion 
We have investigated by immunohistochemistry the expression of a recently identified 
protein, ERBIN 17,18, and of its binding partner, Erb-B2, an orphan receptor of the EGFR family, in 
normal human skin and in cutaneous carcinomas. The results indicate that both ERBIN and Erb-B2 
are primarily localized at the plasma membrane in differentiated keratinocytes and duct cells of 
eccrine glands in normal human skin. While in KA and SCC the expression pattern of ERBIN and 
Erb-B2 are either normal or only marginally affected, their expression level and subcellular 
distribution appear to be significantly altered in BCC. 
In normal human skin, ERBIN and Erb-B2 have a similar expression pattern in the 
epidermis, eccrine sweat glands and hair follicles. Specifically, in the upper layers of the 
epidermis, both proteins are found along the plasma membrane. In contrast, cells of the basal cell 
layer display a diffuse cytoplasmic staining with the anti-ERBIN antibody, while they do not 
significantly express Erb-B2, at least as assessed utilizing the mAb 3B5. Both ERBIN and Erb-B2 
exhibited a cytosolic distribution in secretory cells of eccrine sweat glands, whereas in duct cells 
they showed a plasma membrane localization. The latter subcellular distribution was also found in 
all layers of hair follicles. The observed expression profile of Erb-B2 is in line with previous 
findings in normal human epidermis 10,12. Collectively, these findings suggest that in vivo ERBIN 
is recruited and localized at cytoplasmic plasma membrane in differentiated and polarized 
epithelial cells, whereas it shows cytosolic distribution in less differentiated cells. This idea is 
supported by our immunofluorescence microscopy and Western blot studies. In fact, in cultured 
nondifferentiated keratinocytes ERBIN has a predominantly cytosolic distribution, whereas upon 
differentiation, ERBIN mainly exhibit a plasma membrane staining. Furthermore, both ERBIN and 
Erb-B2 show a plasma membrane localization in SCC which is not detected in the less 
differentiated tumour cells from BCC. Finally, immunoblot analyses disclosed that the content of 
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ERBIN was higher in the plasma membrane fractions obtained from differentiated keratinocytes 
than in those obtained from undifferentiated cells. 
Previous histochemical studies have provided contradictory data about the expression of 
Erb-B2. Maguire et al. 12 reported that the expression of Erb-B2 is reduced in BCC, but is either 
increased or unchanged in SCC. In contrast, Ahmed et al. 13 described an increased expression of 
Erb-B2 in SCC when compared with BCC, whereas normal human epidermis did not express Erb-
B2. In the study of Suo et al. 14 there was no immune reactivity for Erb-B2 in any of the cases of 
SCC tested. Finally, recent studies have found that in both BCC and SCC the mRNA level of Erb-
B2 remains unchanged 3 
The present study discloses that in a substantial number of cases of BCC there is 
concomitant overexpression of both ERBIN and Erb-B2, whereas in a number of cases of SCC 
these two proteins appeared to be reduced. With regard to BCC, our findings further indicate that 
the subcellular distribution of both Erb-B2 and ERBIN is altered, as both were frequently found in 
aggregates in the cytoplasm. In this context, Stoll et al. 10 found that Erb-B2 has a cytoplasmic 
distribution in the carcinomatous A431 keratinocyte cell line. These authors suggested that Erb-B2 
is sequestered intracellularly and contributes to the development of the malignant cellular 
phenotype by activating Erb-B1-dependent growth/survival signals, while evading Erb-B2-
dependent differentiation signals. 10 Although ultrastructural studies are required, better  to define 
the nature of these cytoplasmic aggregates, light microscopy of our immunoperoxidase-stained 
sections of BCC at high magnification suggest that they correspond to endocytic vesicles 
containing internalized receptors and associated proteins (Fig 4). Finally, aggregates of ERBIN 
and Erb-B2 were found in a high proportion of the cells that form the peripheral palisaded layer of 
the tumoral BCC islands. As ERBIN can bind BP230 and the b4 integrin subunit, two components 
of the hemidesmosomes, whereas Erb-B2 can associate with the b4 integrin subunit, it is 
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conceivable that some of these aggregates result from the altered expression of BP230 and the b4 
integrin subunit previously demonstrated in BCC 27, 28. 
By analogy to what was found in intestinal epithelial cells 17, it is possible that ERBIN 
critically affects the topogenic fate of Erb-B2 and hence its expression and distribution on the 
surface of differentiated keratinocytes. If this holds true, the altered cellular distribution of both 
ERBIN and Erb-B2 in BCC is likely to have a negative impact on Erb-B2-dependent 
differentiation signals and may explain, at least in part, the poorly differentiated nature of BCC. 
Indirect support for this hypothesis derives from the observation that the polarized distribution of 
both ERBIN and Erb-B2 is largely unaffected in differentiated tumors such as KA and SCC. 
However, differences exist between KA and SCC for both ERBIN and Erb-B2. Indeed, for both 
ERBIN and Erb-B2 there was no alteration either in their expression level or in their subcellular 
distribution in KA when compared to normal human skin, whereas in SCC their staining patterns 
were heterogenous within the same tumour and between tumours. However there was no apparent 
correlation between the degree of tumor differentiation in SCC and the alterations in expression 
and distribution of both ERBIN and Erb-B2. 
In the light of our findings in BCC and SCC and based on the biological activities of Erb-
B2 and its ability to associate with ERBIN, it is conceivable that the disturbed expression or 
functioning of these proteins affects the development of malignant tumours such as BCC and SCC. 
Although it is likely that ERBIN and Erb-B2 synergistically cooperate in signalling pathways 
affecting cell growth and differentiation, further studies are needed to dissect these effects. We are 
currently generating a transgenic mouse model with constitutive overexpression of ERBIN in the 
epidermis. This mouse model will, it is hoped, provide a powerful tool for understanding the role 
of ERBIN in the control of cell proliferation and differentiation and its interplay with Erb-B2. 
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Legend of figures 
Figure 1 
(A) Immunoblot analysis with anti-ERBIN polyclonal antibody (pAb) 139 and pAb 1646 of whole 
cell extracts (40 µg per lane) from HaCaT cell line (lane 1), undifferentiated (lane 2) or 
differentiated (lane 3) immortalized keratinocyte cell line. Molecular weight markers: 175 kDa, 83 
kDa, 62 kDa. 
(B) Immunoblot analysis with the pAb 1646 anti-ERBIN antibody (top panel), with the anti-
integrin b4 subunit antibody (middle panel) and the antikeratin 14 antibody (bottom panel) of 
cytosolic (Cyt), membrane (Mb) and cytoskeletal (CSK) cell fractions (25 µg per lane) prepared 
from undifferentiated (KERAT Low Ca2+) or differentiated (KERAT High Ca2+) immortalized 
keratinocytes.  
 
Figure 2 
Expression of ERBIN in an undifferentiated (A) and differentiated (B) immortalized keratinocytes 
cell line by immunofluorescence microscopy. In undifferentiated cells the anti-ERBIN antibody 
shows a predominant diffuse cytosolic staining with only marginal staining of the plasma 
membrane (A). In contrast, in differentiated cells, a predominant membrane staining of ERBIN is 
found (B). Bar: 25 µm 
 
Figure 3 
Immunohistochemistry for ERBIN (A, C, E) and Erb-B2 (B, D, F) in human epidermis (A, B), hair 
follicles (C, D), and sweat eccrine glands (E, F). In the epidermis, anti-ERBIN antibody pAb 139 
produced a diffuse cytoplasmic staining of the basal keratinocytes and a plasma membrane staining 
in the suprabasal and differentiated keratinocytes (A). A similar plasma membrane staining was 
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also identified in all layers of hair follicles (C). In eccrine glands (E), a diffuse ERBIN staining 
was found in the cytoplasm of secretory cells and myoepithelial cells (arrowhead). In addition, 
cells lining the duct lumen showed an intercellular staining. Erb-B2 staining was predominantly 
found at the level of plasma membrane in the upper epidermis (B) and in all layers of hair follicles 
(D). In eccrine glands (F), Erb-B2 was diffusely distributed in the cytoplasm of cells located in the 
secretory portions, whereas duct cells showed an intercellular staining. Bar = 20 µm 
 
Figure 4 
Immunohistochemistry for ERBIN (A, C, E, G) and Erb-B2 (B, D, F, H) in basal cell carcinoma 
(BCC) (A-D), squamous cell carcinoma (SCC)(E, F) and keratoacanthoma (G, H). In BCC, anti-
ERBIN (A, C) and anti-Erb-B2 (B, D) antibodies produced a diffuse cytoplasmic staining. In 
addition, both ERBIN and Erb-B2 were observed in cytoplasmic aggregates (A, B). At higher 
magnification these aggregates appeared to consist of many individual cytosolic vesicles (C, D). 
Insert (A) shows the peripheral edge of BCC, the tumoral cells of which contain cytosolic 
aggregates(E).  
Representative example of the immunostaining of ERBIN in SCC with a diffuse cytosolic 
distribution. Some cells displayed a strong labelling (arrowhead). In SCC, Erb-B2 staining is 
reduced and is predominantly found at the plasma membrane in tumoral cells located at distance 
from the underlying stromal tissue (arrowhead) (F). In KA, peripheral cells displayed a diffuse 
cytoplasmic staining whereas in the innermost layers both ERBIN (G) and Erb-B2 (H) gave a 
prominent plasma membrane staining. Bar = 20 µm 
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case n° BCC SCC 
 Erbin Erb-B2 Erbin Erb-B2 
1 C, A C, A C, M - 
2 C, A 
 
C, A C C, M 
3 C, A, M C, A C, M C, M 
4 C C C, M C, M 
5 C, A C, A C C 
6 C C, A C - 
7 C, A, M C, A, M C C, M 
8 C, A C, A C C, M 
9 C, A C, A C, M C 
10 C C C, M C, M 
11 C, A C, M C C, M 
12 C, A C, A C C 
13 C, A C, A   
14 C, A C, A   
15 C, A C, A   
 
Table I : Cellular distribution of Erbin and Erb-B2in basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC). C, cytosolic staining; M, plasma membrane staining; A, cytoplasmic 
aggregates.  
 
case n°    BCC 
 
SCC 
 Erbin Erb-B2 Erbin Erb-B2 
1 = = - 0 
2 = = - - 
3 = + - - 
4 = = - - 
5 = + = - 
6 = = = 0 
7 = = = = 
8 = = = - 
9 + + = - 
10 + + = - 
11 + + = - 
12 + + = - 
13 + +   
14 + +   
15 + +   
 
Table II : Relative staining intensity of ERBIN and Erb-B2 in basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). The comparison was based on the staining intensity of the 
adjacent normal epidermis present in the same section. 0, no staining ; -, staining lower than in 
normal epidermis; =,staining similar to normal epidermis; +, staining stronger than in normal 
epidermis 
 
 
 
 
 
